GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ALKS-8700 | ALKS8700 | BIIB098 | Vumerity®
                                 
                                                         
                            
                            
                            
                                 
                                
                                diroximel fumarate is an approved drug (FDA (2019), EMA (2021)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Diroximel fumarate is a novel oral fumarate prodrug. It is rapidly converted to monomethyl fumarate, which is the same active metabolite of dimethyl fumarate.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Palte MJ, Wehr A, Tawa M, Perkin K, Leigh-Pemberton R, Hanna J, Miller C, Penner N. (2019)
                                         Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Adv Ther, 36 (11): 3154-3165. [PMID:31538304]  |